Study Shows 73% Survival at Three Years by Combining Radiation Therapy and Chemotherapy March 31, 2015Vol.38 No.03
Drugs & Targets FDA Grants Accelerated Approval to Farydak For Patients with Multiple Myeloma March 31, 2015Vol.38 No.03
Provenge Immune Response Continued For Two Years in Phase II Study in BRPC March 31, 2015Vol.38 No.03
Phase III Trial of Imbruvica Unblinded Following Significant Increase in PFS March 31, 2015Vol.38 No.03
Drugs & Targets Rich Pharmaceuticals plans to launch clinical trials at Khon Kaen University in Thailand March 27, 2015Vol.41 No.12
Drugs & Targets Teikoku Pharma USA submits NDA for alcohol-free docetaxel formulation March 27, 2015Vol.41 No.12
In Brief FDA’s Richard Pazdur Named by Fortune As one of 50 “World’s Greatest Leaders” March 27, 2015Vol.41 No.12
